Global Market Study on Liposomes: Significant Adoption of Liposomes being Witnessed to Enhance Drug Delivery
Liposomes Market Segmented By Simple Liposomes, Formulated Liposomes, Doxorubicin Liposomes, Amphotericin B Liposomes, Paclitaxel Liposomes, Cytarabine Liposomes, Irinotecan Liposomes, Cisplatin Liposomes, Vaccine Product in Drug Delivery, Gene Delivery/Transfection, Contrast Agents for Medical Imaging, Model Cell Membranes
The world has been observing rising demand for drugs, led by an increase in the number of oncology diseases, fungal disorders, Hepatitis A, influenza, Kaposi’s sarcoma, and other diseases. Cigarette smoking is the most common and known factor in developing cancer.
According to the WHO, breast cancer is impacting 2.1 million women each year, and was the most prevalent cancer among women in 2018. Growing incidence of cancer is expected to favour the demand for liposomal drugs such as doxorubicin, irinotecan, mifamurtide, and others.
Also, rising incidence of fungal disorders is boosting the demand for liposomal formulations of Amphotericin B, thereby leading to the expansion of the liposomes market size.
Find Out More about the Report Coverage
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharma Industries Ltd
- Baxter AG
- Sanofi SA
- Bristol Myers Squibb
- Mylan NV
- GlaxoSmithKline Plc.
- Creative Biolabs
- Precision NanoSystems Inc.
- SkyePharma Inc.
- Luye Pharma Group
- Encapsula NanoSciences LLC
- Nanovex Biotechnologies SL
- Gilead Sciences, Inc.
- Avanti Polar Lipids, Inc.
- Fujifilm Holdings Corporation
Liposomes Market Trends
Greater Adoption of Quality by Design (QbD) Over Traditional Processes: Adoption of rational-based approaches such as QbD over empirical and simulation-based approaches has been contributing to streamlined processes. QbD is based on a fact-based rational approach, and helps in more robust decision-making as compared to traditional approaches based on trial and error.
Furthermore, global regulatory authorities are converging toward process and regulatory harmonization for the manufacturing of liposomal formulation. The QbD approach is expected to witness increased popularity and rising adoption. Adoption of QbD in manufacturing processes is expected to increasingly contribute toward better quality, gradation, and consistency of excipient supply, which, in turn, will lead to better final products/drugs.
Increasing Adoption of Generic Liposome Drugs: Market competition is increasing due to the growing adoption of low-cost generic products as compared to branded products. According to the U.S. Centers for Medicare & Medicaid Services, in 2017, the generic dispensing rate for generic drugs was 82.2% in Part D of CMS. Prices of liposomal drugs have fallen due to the entry of new generic drugs.
Increasing adoption of generic liposomal drugs as compared to branded drugs provides higher treatment accessibly and leads to high liposomes market growth. For instance, in December 2016, Dr Reddy's Laboratories Ltd. announced FDA approval for the doxorubicin hydrochloride liposome injection in the U.S. market.
Growing Adoption of Liposomal Contrast Imaging Agents: Liposomes are to be tailored for diagnostic, therapeutic, and image-guided drug delivery. Paramagnetic liposomes are widely used in image-guided drug delivery and molecular and cellular imaging.
Paramagnetic liposomes loaded with drugs have been used for therapeutic interventions. Liposomes have long been offered as a vehicle to deliver paramagnetic ions. Growing imaging procedures such as MRIs, CT scans, and SPECT imaging is expected to complement the growth of the global liposomes market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
?Competitive Landscape of Liposomes Market
The global liposomes market is fragmented in nature; huge number of manufacturers are present in this market space. Key players operating in the liposomes market across the globe include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson, Bristol Myers Squibb Company, GlaxoSmithKline Plc., and SkyePharma Inc.
Manufacturers are focusing on acquisitions, mergers, and partnerships to expand their product portfolios and increase revenue across different geographies. For instance, in November 2019, Bristol Myers Squibb Company completed the acquisition of Celgene Corporation. Moreover, in December 2019, Janssen Pharmaceutical Company of Johnson & Johnson acquired all rights of XBiotech Inc.’s investigational compound bermekimab for the treatment of multiple dermatological indications.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
COVID-19 Impact on Liposomes Market
Many pharmaceutical and biotechnology manufacturers are focusing on the development of efficient and safe vaccines for COVID-19. New technological platforms and advanced genetic engineering procedures are required to obtain a COVID?19 vaccine. Manufacturers are focusing on expanding clinical trials to solve the epidemiological problem and establishment of large-scale production of these vaccines. Manufacturers are switching to advanced production platforms from tradition platforms.
Companies are focusing on partnerships and agreements to co-develop vaccines for combating the COVID?19 pandemic. For instance, in May 2020, CanSino Biologics Inc. and Precision NanoSystems (PNI) announced a co-development contract of an mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19 with NanoAssemblr manufacturing technology.
Explore Persistence Market Research’s expertise in promulgation of the business !
The research report on the liposomes market provides recommendations, overview of the market, and estimations of market growth over the next decade. Growing prevalence of fungal diseases and cancer, and increasing adoption of liposomal vaccines, are responsible for the growth of the global liposomes market. North America and Europe hold a substantial liposomes market share. Increasing liposomal drug launches and ongoing clinical trials on liposomes will favour the growth of the global liposomes market over the coming years.
Key Segments of Liposomes Market
PMR’s study on the liposomes market offers information divided into four important segments—product, application, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in PMR’s Liposomes Market Report
- Which regions will continue to remain the most profitable regional markets for liposomes market players?
- Which factors will induce a change in the demand for liposomes during the assessment period?
- What are the different opportunities available for emerging players in the liposomes market?
- How are supply-side and demand-side drivers impacting the liposomes market?
- How will changing trends impact the liposomes market?
- How can market players capture the low-hanging opportunities in the liposomes market in developed regions?
- Which companies are leading the liposomes market?
- What are the winning strategies of stakeholders in the liposomes market to upscale their position in this landscape?